161 related articles for article (PubMed ID: 25003983)
1. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer.
Wang T; Liu Z; Guo S; Wu L; Li M; Yang J; Chen R; Xu H; Cai S; Chen H; Li W; Wang L; Hu Z; Zhuang Q; Xu S; Wang L; Liu J; Ye Z; Ji JY; Wang C; Chen K
Oncotarget; 2014 Jun; 5(11):3611-21. PubMed ID: 25003983
[TBL] [Abstract][Full Text] [Related]
2. CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling.
Wang T; Guo S; Liu Z; Wu L; Li M; Yang J; Chen R; Liu X; Xu H; Cai S; Chen H; Li W; Xu S; Wang L; Hu Z; Zhuang Q; Wang L; Wu K; Liu J; Ye Z; Ji JY; Wang C; Chen K
Oncotarget; 2014 Nov; 5(21):10293-306. PubMed ID: 25296973
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
4. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
5. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
6. CAMK2N1 suppresses hepatoma growth through inhibiting E2F1-mediated cell-cycle signaling.
Peng JM; Tseng RH; Shih TC; Hsieh SY
Cancer Lett; 2021 Jan; 497():66-76. PubMed ID: 33068700
[TBL] [Abstract][Full Text] [Related]
7. KLF9, a transcription factor induced in flutamide-caused cell apoptosis, inhibits AKT activation and suppresses tumor growth of prostate cancer cells.
Shen P; Sun J; Xu G; Zhang L; Yang Z; Xia S; Wang Y; Liu Y; Shi G
Prostate; 2014 Jun; 74(9):946-58. PubMed ID: 24737412
[TBL] [Abstract][Full Text] [Related]
8. MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.
Wu C; Miao C; Tang Q; Zhou X; Xi P; Chang P; Hua L; Ni H
J Cell Mol Med; 2020 Feb; 24(3):2098-2108. PubMed ID: 31876385
[TBL] [Abstract][Full Text] [Related]
9. Autocrine Activation of CHRM3 Promotes Prostate Cancer Growth and Castration Resistance via CaM/CaMKK-Mediated Phosphorylation of Akt.
Wang N; Yao M; Xu J; Quan Y; Zhang K; Yang R; Gao WQ
Clin Cancer Res; 2015 Oct; 21(20):4676-85. PubMed ID: 26071486
[TBL] [Abstract][Full Text] [Related]
10. miR-182-5p Promotes Growth in Oral Squamous Cell Carcinoma by Inhibiting CAMK2N1.
Li N; Nan CC; Zhong XY; Weng JQ; Fan HD; Sun HP; Tang S; Shi L; Huang SX
Cell Physiol Biochem; 2018; 49(4):1329-1341. PubMed ID: 30205384
[TBL] [Abstract][Full Text] [Related]
11. MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity.
Wang Y; Shao N; Mao X; Zhu M; Fan W; Shen Z; Xiao R; Wang C; Bao W; Xu X; Yang C; Dong J; Yu D; Wu Y; Zhu C; Wen L; Lu X; Lu YJ; Feng N
Oncotarget; 2016 Jul; 7(30):47444-47464. PubMed ID: 27329728
[TBL] [Abstract][Full Text] [Related]
12. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
Stoyanova T; Riedinger M; Lin S; Faltermeier CM; Smith BA; Zhang KX; Going CC; Goldstein AS; Lee JK; Drake JM; Rice MA; Hsu EC; Nowroozizadeh B; Castor B; Orellana SY; Blum SM; Cheng D; Pienta KJ; Reiter RE; Pitteri SJ; Huang J; Witte ON
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6457-E6466. PubMed ID: 27694579
[TBL] [Abstract][Full Text] [Related]
13. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
14. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
15. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
Ren S; Liu Y; Xu W; Sun Y; Lu J; Wang F; Wei M; Shen J; Hou J; Gao X; Xu C; Huang J; Zhao Y; Sun Y
J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of CAMK2N1 due to DNA Hypermethylation Mediated by DNMT1 that Promotes the Progression of Prostate Cancer.
Peng W; Feng H; Pang L; Zhang J; Hao Y; Wei X; Xia Q; Wei Z; Song W; Wang S; Liu J; Chen K; Wang T
J Oncol; 2023; 2023():4539045. PubMed ID: 36755811
[TBL] [Abstract][Full Text] [Related]
18. Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance.
Li S; Hu MG; Sun Y; Yoshioka N; Ibaragi S; Sheng J; Sun G; Kishimoto K; Hu GF
Mol Cancer Res; 2013 Oct; 11(10):1203-14. PubMed ID: 23851444
[TBL] [Abstract][Full Text] [Related]
19. Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
Bjerke GA; Yang CS; Frierson HF; Paschal BM; Wotton D
Oncogene; 2014 Jul; 33(28):3660-7. PubMed ID: 23995785
[TBL] [Abstract][Full Text] [Related]
20. A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer.
Su B; Gao L; Baranowski C; Gillard B; Wang J; Ransom R; Ko HK; Gelman IH
PLoS One; 2014; 9(7):e101411. PubMed ID: 24983969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
